Wang R, Deng X, Yoshioka Y, Vougiouklakis T, Park J, Suzuki T, et al. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells. Cancer Sci. 2017;108:1203-1209 pubmed 出版商

Morena D, Maestro N, Bersani F, Forni P, Lingua M, Foglizzo V, et al. Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. elife. 2016;5: pubmed 出版商

Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S, et al. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017;77:3551-3563 pubmed 出版商

Mattsson J, Brunnström H, Jabs V, Edlund K, Jirstrom K, Mindus S, et al. Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer. 2016;16:603 pubmed 出版商

Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, et al. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. elife. 2015;4:e09811 pubmed 出版商

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, Alsaati T, Beau I, et al. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget. 2015;6:30149-64 pubmed 出版商

Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211-9 pubmed 出版商

Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, et al. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). Appl Immunohistochem Mol Morphol. 2015;23:60-70 pubmed 出版商

Doble B, Tan M, Harris A, Lorgelly P. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Rev Mol Diagn. 2015;15:235-54 pubmed 出版商

Zhang K, Deng H, Cagle P. Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update. Arch Pathol Lab Med. 2014;138:1611-28 pubmed 出版商

Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, et al. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol. 2014;9:1470-6 pubmed 出版商

Cha Y, Lee J, Kim H, Lim S, Cho B, Lee C, et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS ONE. 2014;9:e103333 pubmed 出版商

Yang L, Li G, Zhao L, Pan F, Qiang J, Han S. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. Tumour Biol. 2014;35:9759-67 pubmed 出版商

Choi P, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014;5:3728 pubmed 出版商

Berghoff A, Birner P, Streubel B, Kenner L, Preusser M. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. APMIS. 2014;122:867-72 pubmed 出版商

Minca E, Lanigan C, Reynolds J, Wang Z, Ma P, Cicenia J, et al. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol. 2014;9:464-8 pubmed 出版商

Feng Y, Minca E, Lanigan C, Liu A, Zhang W, Yin L, et al. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. J Thorac Oncol. 2014;9:646-53 pubmed 出版商

Yang J, Zhang X, Su J, Xu C, Zhou Q, Tian H, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20:1383-92 pubmed 出版商

Shan L, Lian F, Guo L, Yang X, Ying J, Lin D. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. Diagn Pathol. 2014;9:3 pubmed 出版商

Han X, Zhang N, Ma L, Lin D, Hao X, Liu Y, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. 2013;463:583-91 pubmed 出版商

Li Y, Pan Y, Wang R, Sun Y, Hu H, Shen X, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS ONE. 2013;8:e69016 pubmed 出版商

Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24:2589-93 pubmed 出版商

Niu H, Zhou Q, Wang F, Shao Q, Guan Y, Wen X, et al. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell Melanoma Res. 2013;26:646-53 pubmed 出版商

Selinger C, Rogers T, Russell P, O Toole S, Yip P, Wright G, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-53 pubmed 出版商

Zhang Y, Jin M, Li L, Zhao H, Zeng X, Jiang L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS ONE. 2013;8:e64821 pubmed 出版商

Roberts P. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics. 2013;7:91-101 pubmed 出版商

Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013;66:705-7 pubmed 出版商

Filtenborg Barnkob B, Bzorek M. Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. Hum Pathol. 2013;44:1656-64 pubmed 出版商

Minca E, Portier B, Wang Z, Lanigan C, Farver C, Feng Y, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15:341-6 pubmed 出版商

Preusser M, Berghoff A, Ilhan Mutlu A, Magerle M, Dinhof C, Widhalm G, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer. 2013;80:278-83 pubmed 出版商

Conklin C, Craddock K, Have C, Laskin J, Couture C, Ionescu D. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51 pubmed 出版商

Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, et al. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology. 2012;83:248-56 pubmed 出版商

Rimkunas V, Crosby K, Li D, Hu Y, Kelly M, Gu T, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-57 pubmed 出版商